Effect of Cannabinoid (THC / CBD 50%) on Hyperalgesia in Patients With Deep Endometriosis (EdomTHC)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Christian Dursteler, MD
- Phone Number: +34.93.227.54.00
- Email: dursteler@clinic.cat
Study Locations
-
-
Catalonia
-
Barcelona, Catalonia, Spain, 08036
- Hospital Clinic de Barcelona
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women between the ages of 18 and 40.
- Diagnosis of deep endometriosis after clinical suspicion and confirmation by imaging test.
- Pain with a score of 4 or more on a numerical visual scale of 11 levels (EVN 0-10) in the last 3 months (includes any type of pain associated with endometriosis: dysmenorrhea, dyspareunia, dyschezia, dysuria and / or pelvic pain).
- Women of childbearing age * should have a negative pregnancy test before inclusion in the study and should commit to using highly effective contraceptive methods (hormonal contraceptives, intrauterine device, intrauterine hormonal release systems, bilateral tubal occlusion, vasectomy the couple, barrier methods and sexual abstinence) during the entire duration of the study and up to 3 months after the end of it.
- Acceptance of participation in the study by signing the informed consent.
Exclusion Criteria:
- Patients previously submitted to open abdominal surgery.
- History of cancer.
- Suspicion or diagnosis of endocrine, cardio-vascular or systemic pathology relevant.
- Pregnancy or anticipation of pregnancy up to 3 months after the end of the study.
- Current breastfeeding.
- Use of hormonal treatment (combined oral contraception, progestin in the 3 months prior to the study, GNRH analogs in the 6 months prior to the start of the study).
- Use of other analgesics different from those allowed in the study.
- Recreational or pharmacological use of cannabinoids.
- Hypersensitivity to cannabinoids or any of the exceptions.
- Known or suspected personal history, or family history of schizophrenia or other psychotic illnesses, severe personality disorder or other major psychiatric disorders.
- Patients with liver or kidney failure, severe cardiovascular disease and a history of epilepsy or recurrent seizures.
- Patients who use concomitant potent enzyme inducers of CYP3A4, such as rifampicin, carbamazepine, phenytoin, phenobarbital, and St. John's wort.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Study arm
Participants are treated with the investigational medical product
|
Participants are treated with cannabinoid derivates with a dose between 1 to 12 puffs, each puffs contains 2,7 mg of delta-9-tetrahidrocannabinol and 2,5 mg of cannabidiol.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pressure threshold in hypogastrium that induces pain
Time Frame: day 30 after treatment initiation
|
Pain threshold versus mechanical stimulation in hypogastrium (anterior central L2 dermatoma) measured in kPa
|
day 30 after treatment initiation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pressure threshold in dermatomes that induces pain
Time Frame: baseline, day 15, day 30 and day 45
|
Umbral of pain versus mechanical stimulation in dermatomes L2 anterior, L2 posterior, and T1 of the dominant upper extremity.
|
baseline, day 15, day 30 and day 45
|
|
Temperature threshold in dermatomes that induces pain
Time Frame: baseline, day 15, day 30 and day 45
|
Umbral sensation versus thermal stimulus (cold heat) in anterior central L2 dermatomes, posterior central L2, and T1 of the dominant upper extremity.
Measured in ºC.
|
baseline, day 15, day 30 and day 45
|
|
Intensity of the general pain
Time Frame: baseline, day 15, day 30 and day 45
|
Intensity of the general pain associated with endometriosis measured by a visual analogue scale (0-10)
|
baseline, day 15, day 30 and day 45
|
|
Anxiety and depression combined scale
Time Frame: baseline, day 15, day 30 and day 45
|
Anxiety and depression measured with the Scale of Anxiety and Hospital Depression Scale (HADS).
|
baseline, day 15, day 30 and day 45
|
|
Quality of Life
Time Frame: baseline, day 15, day 30 and day 45
|
Quality of Life measured through the EQ-5D-5L questionnaire.
|
baseline, day 15, day 30 and day 45
|
|
Central sensitivity
Time Frame: baseline, day 15, day 30 and day 45
|
Central sensitivity measured with the Central Sensitization Inventory (CSI) questionnaire.
|
baseline, day 15, day 30 and day 45
|
|
Cognitive disorder measured by a list of words
Time Frame: baseline, day 15, day 30 and day 45
|
Cognitive disorder measured by a list of words (immediate memory and retention) and digits (attentional capacity) of the Wechsler Memory Scale (WMS-III).
|
baseline, day 15, day 30 and day 45
|
|
about sleep quality
Time Frame: baseline, day 15, day 30 and day 45
|
Visual analogue scale 0-10 about sleep quality
|
baseline, day 15, day 30 and day 45
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2018-004378-92
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.